ARYx Therapeutics, Inc. Stock

ARYX

US0433871094

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 09:47:07 2023-06-26 EDT			5-day change	1st Jan Change
0.001200 ^USD	+1,100.00%		-.--%	-

Valuation: ARYx Therapeutics, Inc.

Market Cap	9.03M 7.92M 7.34M 6.75M 12.73M 870M 12.89M 87.57M 34.27M 426M 33.91M 33.18M 1.47B	P/E 2008	-1.76x	P/E 2009	-2.66x
Enterprise Value	11.41M 10M 9.26M 8.53M 16.08M 1.1B 16.27M 111M 43.26M 538M 42.81M 41.89M 1.86B	EV / Sales 2008	4,019,605x	EV / Sales 2009	-
Free-Float	100%	Yield 2008 *	-	Yield 2009	-

* Estimated data More valuation ratios

Press Releases: ARYx Therapeutics, Inc.

11-03-09	ARYX THER : ARYx Therapeutics Informed of Additional Delay by FDA and Begins Wind-Down of Operations	BU
10-12-23	ARYX THER : ARYx Therapeutics Clarifies Current Status of Operations	BU
10-12-21	ARYX THER : ARYx Therapeutics to Transfer to the NASDAQ Capital Market	BU
10-12-15	ARYX THER : ARYx Therapeutics Provides Update on Company Status	BU
10-11-15	ARYX THER : ARYx Therapeutics Reports Third Quarter Results	BU

More press releases

ARYx Therapeutics, Inc. is a United States-based pharmaceutical Company. The Company is developing a proprietary portfolio of patient-targeted, first-in-class monoclonal antibodies designed to treat seriously ill patients with difficult-to-treat diseases. It is engaged in retrometabolic drug design that focuses on the safety of oral therapies for chronic disease. The Companys clinical compounds include naronapride (ATI-7505) for gastrointestinal disorders; budiodarone (ATI-2042, for the treatment of atrial fibrillation; tecarfarin (ATI-5923) for the treatment of anticoagulation; and ATI-9242, for psychiatric disorders.

Employees

Sector

Biotechnology & Medical Research

More about the company

Stock Market
Stocks
ARYX Stock

As early as today, start finding the best investment opportunities!

5 years	0		0.04
10 years	0		0.05

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARYX THERAPEUTICS, INC.	+1,100.00%	-.--%	-	-.--%	33
WUXI APPTEC CO., LTD.	+1.80%	-0.83%	+52.79%	+86.50%	55.57B
ARGENX SE	-0.45%	+0.83%	+55.43%	+58.03%	54.26B
BIONTECH SE	+0.18%	+2.13%	-15.22%	-14.97%	23.35B
INSMED INCORPORATED	+1.50%	-1.35%	+5.68%	+415.28%	23.54B
WUXI BIOLOGICS (CAYMAN) INC.	+0.05%	-1.77%	+38.71%	-4.22%	20.32B
GENMAB A/S	-0.15%	-2.51%	+33.47%	-31.38%	17.36B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.08%	-3.63%	+36.77%	+547.87%	15.59B
PHARMAESSENTIA CORPORATION	0.00%	-2.08%	+165.40%	+297.92%	14.96B
EXELIXIS, INC.	+1.06%	+0.63%	+26.80%	+185.02%	14.11B
Average	+110.51%	-0.96%	+44.43%	+154.00%	23.91B
Weighted average by Cap.	+0.61%	-1.21%	+43.98%	+135.37%

	2008	2009
Net sales	19.72 17.29 16.02 14.74 27.8 1.9K 28.14 191.18 74.81 930.95 74.04 72.45 3.21K	-
Net income	-31.22M -27.36M -25.35M -23.34M -44M -3.01B -44.54M -303M -118M -1.47B -117M -115M -5.09B	-33.17M -29.07M -26.94M -24.79M -46.75M -3.19B -47.32M -321M -126M -1.57B -125M -122M -5.41B
Net Debt	-29.9 -26.21 -24.29 -22.35 -42.15 -2.88K -42.66 -289.86 -113.43 -1.41K -112.26 -109.84 -4.87K	2.37 2.08 1.93 1.77 3.34 228.34 3.38 22.98 8.99 111.91 8.9 8.71 386.39

ARYx Therapeutics, Inc. Stock

Stocks

ARYX

US0433871094

Biotechnology & Medical Research

Valuation: ARYx Therapeutics, Inc.

Press Releases: ARYx Therapeutics, Inc.

Quotes and Performance

Course Extremes

Bio Therapeutic Drugs

Financials

Company Profile